Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Growth 2025-2031

Publication ID:

LPI04252537

Publication Date:

April 25, 2025

Pages:

140

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The polyvalent streptococcus pneumoniae active immunizing agent is a vaccine that mainly prevents pneumonia caused by Streptococcus pneumoniae. It contains a variety of serotypes that often cause streptococcus pneumoniae infection. After vaccination, it can effectively reduce the risk of pneumonia infection.
United States market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Polyvalent Streptococcus Pneumoniae Active Immunizing Agent players cover GlaxoSmithKline, LG Chem, Merck, Panacea Biotec, AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淧olyvalent Streptococcus Pneumoniae Active Immunizing Agent Industry Forecast鈥� looks at past sales and reviews total world Polyvalent Streptococcus Pneumoniae Active Immunizing Agent sales in 2024, providing a comprehensive analysis by region and market sector of projected Polyvalent Streptococcus Pneumoniae Active Immunizing Agent sales for 2025 through 2031. With Polyvalent Streptococcus Pneumoniae Active Immunizing Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Polyvalent Streptococcus Pneumoniae Active Immunizing Agent industry.
This Insight Report provides a comprehensive analysis of the global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Polyvalent Streptococcus Pneumoniae Active Immunizing Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent.
This report presents a comprehensive overview, market shares, and growth opportunities of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
9-Valent
13-Valent
23-Valent
Others
Segmentation by Application:
Hospital
Community Clinics
Public Health Agencies
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
LG Chem
Merck
Panacea Biotec
AstraZeneca
Pfizer
Shire
Pnuvax Incorporated
Serum Institute
Shinogi
Shenzhen Kangtai Biological Products
SK Bioscience
Walvax Biotechnology
Eli Lilly
Abera
Sanofi
Genentech
Key Questions Addressed in this Report
What is the 10-year outlook for the global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent market?
What factors are driving Polyvalent Streptococcus Pneumoniae Active Immunizing Agent market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Polyvalent Streptococcus Pneumoniae Active Immunizing Agent market opportunities vary by end market size?
How does Polyvalent Streptococcus Pneumoniae Active Immunizing Agent break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent by Country/Region, 2020, 2024 & 2031
2.2 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Segment by Type
2.2.1 9-Valent
2.2.2 13-Valent
2.2.3 23-Valent
2.2.4 Others
2.3 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Type
2.3.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Market Share by Type (2020-2025)
2.3.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue and Market Share by Type (2020-2025)
2.3.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sale Price by Type (2020-2025)
2.4 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Segment by Application
2.4.1 Hospital
2.4.2 Community Clinics
2.4.3 Public Health Agencies
2.4.4 Others
2.5 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Application
2.5.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sale Market Share by Application (2020-2025)
2.5.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue and Market Share by Application (2020-2025)
2.5.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Breakdown Data by Company
3.1.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Sales by Company (2020-2025)
3.1.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Market Share by Company (2020-2025)
3.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Revenue by Company (2020-2025)
3.2.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue by Company (2020-2025)
3.2.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue Market Share by Company (2020-2025)
3.3 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sale Price by Company
3.4 Key Manufacturers Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Location Distribution
3.4.2 Players Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent by Geographic Region
4.1 World Historic Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Size by Geographic Region (2020-2025)
4.1.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Size by Country/Region (2020-2025)
4.2.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Sales by Country/Region (2020-2025)
4.2.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Revenue by Country/Region (2020-2025)
4.3 Americas Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Growth
4.4 APAC Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Growth
4.5 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Growth
4.6 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales Growth
5 Americas
5.1 Americas Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Country
5.1.1 Americas Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Country (2020-2025)
5.1.2 Americas Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue by Country (2020-2025)
5.2 Americas Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Type (2020-2025)
5.3 Americas Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Region
6.1.1 APAC Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Region (2020-2025)
6.1.2 APAC Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue by Region (2020-2025)
6.2 APAC Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Type (2020-2025)
6.3 APAC Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent by Country
7.1.1 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Country (2020-2025)
7.1.2 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue by Country (2020-2025)
7.2 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Type (2020-2025)
7.3 Europe Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent by Country
8.1.1 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Country (2020-2025)
8.1.2 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Revenue by Country (2020-2025)
8.2 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Type (2020-2025)
8.3 Middle East & Africa Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent
10.3 Manufacturing Process Analysis of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent
10.4 Industry Chain Structure of Polyvalent Streptococcus Pneumoniae Active Immunizing Agent
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Distributors
11.3 Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Customer
12 World Forecast Review for Polyvalent Streptococcus Pneumoniae Active Immunizing Agent by Geographic Region
12.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Market Size Forecast by Region
12.1.1 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Forecast by Region (2026-2031)
12.1.2 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Forecast by Type (2026-2031)
12.7 Global Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 LG Chem
13.2.1 LG Chem Company Information
13.2.2 LG Chem Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.2.3 LG Chem Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 LG Chem Main Business Overview
13.2.5 LG Chem Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.3.3 Merck Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Panacea Biotec
13.4.1 Panacea Biotec Company Information
13.4.2 Panacea Biotec Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.4.3 Panacea Biotec Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Panacea Biotec Main Business Overview
13.4.5 Panacea Biotec Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.5.3 AstraZeneca Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.6.3 Pfizer Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Shire
13.7.1 Shire Company Information
13.7.2 Shire Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.7.3 Shire Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Shire Main Business Overview
13.7.5 Shire Latest Developments
13.8 Pnuvax Incorporated
13.8.1 Pnuvax Incorporated Company Information
13.8.2 Pnuvax Incorporated Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.8.3 Pnuvax Incorporated Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Pnuvax Incorporated Main Business Overview
13.8.5 Pnuvax Incorporated Latest Developments
13.9 Serum Institute
13.9.1 Serum Institute Company Information
13.9.2 Serum Institute Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.9.3 Serum Institute Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Serum Institute Main Business Overview
13.9.5 Serum Institute Latest Developments
13.10 Shinogi
13.10.1 Shinogi Company Information
13.10.2 Shinogi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.10.3 Shinogi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Shinogi Main Business Overview
13.10.5 Shinogi Latest Developments
13.11 Shenzhen Kangtai Biological Products
13.11.1 Shenzhen Kangtai Biological Products Company Information
13.11.2 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.11.3 Shenzhen Kangtai Biological Products Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Shenzhen Kangtai Biological Products Main Business Overview
13.11.5 Shenzhen Kangtai Biological Products Latest Developments
13.12 SK Bioscience
13.12.1 SK Bioscience Company Information
13.12.2 SK Bioscience Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.12.3 SK Bioscience Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 SK Bioscience Main Business Overview
13.12.5 SK Bioscience Latest Developments
13.13 Walvax Biotechnology
13.13.1 Walvax Biotechnology Company Information
13.13.2 Walvax Biotechnology Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.13.3 Walvax Biotechnology Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Walvax Biotechnology Main Business Overview
13.13.5 Walvax Biotechnology Latest Developments
13.14 Eli Lilly
13.14.1 Eli Lilly Company Information
13.14.2 Eli Lilly Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.14.3 Eli Lilly Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Eli Lilly Main Business Overview
13.14.5 Eli Lilly Latest Developments
13.15 Abera
13.15.1 Abera Company Information
13.15.2 Abera Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.15.3 Abera Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Abera Main Business Overview
13.15.5 Abera Latest Developments
13.16 Sanofi
13.16.1 Sanofi Company Information
13.16.2 Sanofi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.16.3 Sanofi Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Sanofi Main Business Overview
13.16.5 Sanofi Latest Developments
13.17 Genentech
13.17.1 Genentech Company Information
13.17.2 Genentech Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Product Portfolios and Specifications
13.17.3 Genentech Polyvalent Streptococcus Pneumoniae Active Immunizing Agent Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Genentech Main Business Overview
13.17.5 Genentech Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂